RxDoctor Payments Data

Elizabeth Groves-Egan, MD

Ophthalmology · Anderson, INNPI 1518122688

Payments from drug & device makers

$1,245in general payments, 2019–2025

Across 34 payments — averaging $36.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$799
  • AbbVie$103
  • Lensar, Inc.$103
  • Bausch & Lomb Americas Inc.$44
  • Johnson & Johnson Surgical Vision, Inc.$39
  • Sun Pharmaceutical Industries Inc.$37
  • plus $119 from 5 others

What the payments were for

  • Food & beverage$1,245100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,245 in reported general payments places this provider in the 45th percentile of 266 ophthalmology providers in Indiana.

See all ophthalmology providers in Indiana

Medicare billing

Part B allowed, 2024
$155,755
Medicare patients
532
Services billed
1,416

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine110$87,396
Cyclosporine67$33,429
XiidraLifitegrast16$23,230
RhopressaNetarsudil Mesylate39$21,484
LumiganBimatoprost32$17,129
RocklatanNetarsudil Mesylat/Latanoprost24$16,862
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol66$12,271
SimbrinzaBrinzolamide/Brimonidine Tart18$11,953
Latanoprost677$11,832
Timolol Maleate239$9,250
Brimonidine Tartrate321$8,887
Prednisolone Acetate308$8,544
TafluprostTafluprost/Pf21$5,957
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat237$5,605
VyzultaLatanoprostene Bunod12$5,522

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$103$107,100154 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$30$38,34663 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$44$28,75228 claims
AlconSimbrinza$799$11,95318 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate$21$5,28027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 266 ophthalmology providers in Indiana.

Other ophthalmology in Anderson

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →